Are you over 18 and want to see adult content?
More Annotations
A complete backup of https://latofonts.com
Are you over 18 and want to see adult content?
A complete backup of https://mcarchitects.it
Are you over 18 and want to see adult content?
A complete backup of https://cordenpharma.com
Are you over 18 and want to see adult content?
A complete backup of https://gamegpu.com
Are you over 18 and want to see adult content?
A complete backup of https://anniversary-gifts-by-year.com
Are you over 18 and want to see adult content?
A complete backup of https://c21-life.com
Are you over 18 and want to see adult content?
A complete backup of https://magritek.com
Are you over 18 and want to see adult content?
A complete backup of https://bundes-verlag.net
Are you over 18 and want to see adult content?
A complete backup of https://tailoredstash.com
Are you over 18 and want to see adult content?
A complete backup of https://nitrc.org
Are you over 18 and want to see adult content?
A complete backup of https://autoevolution.com
Are you over 18 and want to see adult content?
A complete backup of https://avalabs.org
Are you over 18 and want to see adult content?
Favourite Annotations
A complete backup of https://construnario.com
Are you over 18 and want to see adult content?
A complete backup of https://palatinetownship-il.gov
Are you over 18 and want to see adult content?
A complete backup of https://ctlandmarks.org
Are you over 18 and want to see adult content?
A complete backup of https://lightbank.com
Are you over 18 and want to see adult content?
A complete backup of https://cimm.com.br
Are you over 18 and want to see adult content?
A complete backup of https://envoyer.io
Are you over 18 and want to see adult content?
A complete backup of https://silvera.fr
Are you over 18 and want to see adult content?
A complete backup of https://petycjeonline.com
Are you over 18 and want to see adult content?
A complete backup of https://agriniopress.gr
Are you over 18 and want to see adult content?
A complete backup of https://nonin.com
Are you over 18 and want to see adult content?
A complete backup of https://egames.com
Are you over 18 and want to see adult content?
A complete backup of https://grimmwelt.de
Are you over 18 and want to see adult content?
Text
PIPELINE - COMPUGEN
Pipeline Overview COM701/PVRIG COM902/TIGIT ILDR2/BAY 1905254 Myeloid Programs Bispecific Products Overview COM701/PVRIG COM902/TIGIT ILDR2/BAY 1905254 Myeloid Programs Bispecific Products Overview Despite significant advances in oncology, there is still a large unmet need in treating patients with solid tumors, especially those with advanced disease. Our approach begins with ourCOM701/PVRIG
COM701/PVRIG. Compugen’s lead candidate, COM701, is a first-in-class immunotherapy targeting PVRIG, a novel immune checkpoint that our team computationally discovered and validated in preclinical studies. Clinical data of COM701, as a monotherapy and in combination with PD-1 blockers, have demonstrated initial signs of antitumor activityCOMPUGEN - OVERVIEW
Compugen is a clinical-stage drug discovery and development company utilizing a broadly applicable, predictive computational discovery platform to identify novel drug targets and new biological pathways and develop therapeutics in the field of cancer immunotherapy. Recognizing the potential of immuno-oncology to shift the cancertreatment
LEADERSHIP - COMPUGEN Leadership Overview Leadership Collaborations Overview Leadership Collaborations Management Compugen’s leadership team is comprised of seasoned executives with deep knowledge and expertise in the biopharmaceutical industry. Anat Cohen-Dayag, Ph.D. President and CEO Ari Krashin Chief Financial and Operating Officer Henry Adewoye, M.D. Senior Vice President and Chief Medical Officer Oliver COMPUGEN - COMPUGEN REPORTS FIRST QUARTER 2021 RESULTS The Company will hold a conference call today, May 13, 2021, at 8:30 AM ET to review its first quarter 2021 results. To access the conference call by telephone, please dial 1-866-744-5399 from the United States, or +972-3-918-0644 internationally. The call will also be available via live webcast through Compugen's website, located atthe
COMPUGEN ANNOUNCES DATA UPDATE FROM COM701 PHASE 1 HOLON, Israel, Feb. 25, 2021 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, reported today updated data from its Phase 1 dose escalation and expansion study of COM701 as a monotherapy, and in a dose escalation combination study with Opdivo® (nivolumab). ). COM701 is a first-in-class investigational COMPUGEN - COMPUGEN EXPANDS CLINICAL COLLABORATION Cohort expansion study expected to commence in the second quarter of 2021 Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, announced today the expansion of its clinical collaboration agreement with Bristol Myers Squibb. Under the amended agreement, Bristol Myers Squibb will supply Opdivo® (nivolumab), its PD-1 COM701 DEMONSTRATES ANTITUMOR ACTIVITY AS … 2 DISCLOSURES • Consulting/Advisor for Bristol Myers Squibb, Merck, Novartis, Replimune • Research funding from Merck, Amgen 2 Ryan J Sullivan, MD et al: COM701 Demonstrates Antitumor Activity as Monotherapy and in Combination with Nivolumab in Patients with Advanced Malignancies, AACR 2020ILDR2/BAY 1905254
ILDR2/BAY 1905254. Myeloid Programs. Bispecific Products. ILDR2 is a novel immune checkpoint target with a unique mechanism of action discovered computationally by Compugen. While ILDR2 demonstrates an inhibitory effect on T cells, consistent with its role as an immune checkpoint ligand, preclinical data suggest that ILDR2 inhibitionexerts its
HOME - COMPUGENABOUT USDISCOVERYPIPELINECOLLABORATIONSINVESTORSCLINICAL TRIALS Our Triple Combination Approach. We believe that the PVRIG pathway we discovered is a potential paradigm shifting target to enhance patient responses to cancer immunotherapies and may provide new treatment options as monotherapy or in combination with other immune checkpoints to expand the reach of cancer immunotherapies to new patientPIPELINE - COMPUGEN
Pipeline Overview COM701/PVRIG COM902/TIGIT ILDR2/BAY 1905254 Myeloid Programs Bispecific Products Overview COM701/PVRIG COM902/TIGIT ILDR2/BAY 1905254 Myeloid Programs Bispecific Products Overview Despite significant advances in oncology, there is still a large unmet need in treating patients with solid tumors, especially those with advanced disease. Our approach begins with ourCOM701/PVRIG
COM701/PVRIG. Compugen’s lead candidate, COM701, is a first-in-class immunotherapy targeting PVRIG, a novel immune checkpoint that our team computationally discovered and validated in preclinical studies. Clinical data of COM701, as a monotherapy and in combination with PD-1 blockers, have demonstrated initial signs of antitumor activityCOMPUGEN - OVERVIEW
Compugen is a clinical-stage drug discovery and development company utilizing a broadly applicable, predictive computational discovery platform to identify novel drug targets and new biological pathways and develop therapeutics in the field of cancer immunotherapy. Recognizing the potential of immuno-oncology to shift the cancertreatment
LEADERSHIP - COMPUGEN Leadership Overview Leadership Collaborations Overview Leadership Collaborations Management Compugen’s leadership team is comprised of seasoned executives with deep knowledge and expertise in the biopharmaceutical industry. Anat Cohen-Dayag, Ph.D. President and CEO Ari Krashin Chief Financial and Operating Officer Henry Adewoye, M.D. Senior Vice President and Chief Medical Officer Oliver COMPUGEN - COMPUGEN REPORTS FIRST QUARTER 2021 RESULTS The Company will hold a conference call today, May 13, 2021, at 8:30 AM ET to review its first quarter 2021 results. To access the conference call by telephone, please dial 1-866-744-5399 from the United States, or +972-3-918-0644 internationally. The call will also be available via live webcast through Compugen's website, located atthe
COMPUGEN ANNOUNCES DATA UPDATE FROM COM701 PHASE 1 HOLON, Israel, Feb. 25, 2021 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, reported today updated data from its Phase 1 dose escalation and expansion study of COM701 as a monotherapy, and in a dose escalation combination study with Opdivo® (nivolumab). ). COM701 is a first-in-class investigational COMPUGEN - COMPUGEN EXPANDS CLINICAL COLLABORATION Cohort expansion study expected to commence in the second quarter of 2021 Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, announced today the expansion of its clinical collaboration agreement with Bristol Myers Squibb. Under the amended agreement, Bristol Myers Squibb will supply Opdivo® (nivolumab), its PD-1 COM701 DEMONSTRATES ANTITUMOR ACTIVITY AS … 2 DISCLOSURES • Consulting/Advisor for Bristol Myers Squibb, Merck, Novartis, Replimune • Research funding from Merck, Amgen 2 Ryan J Sullivan, MD et al: COM701 Demonstrates Antitumor Activity as Monotherapy and in Combination with Nivolumab in Patients with Advanced Malignancies, AACR 2020ILDR2/BAY 1905254
ILDR2/BAY 1905254. Myeloid Programs. Bispecific Products. ILDR2 is a novel immune checkpoint target with a unique mechanism of action discovered computationally by Compugen. While ILDR2 demonstrates an inhibitory effect on T cells, consistent with its role as an immune checkpoint ligand, preclinical data suggest that ILDR2 inhibitionexerts its
COMPUGEN - COMPUGEN REPORTS FIRST QUARTER 2021 RESULTS The Company will hold a conference call today, May 13, 2021, at 8:30 AM ET to review its first quarter 2021 results. To access the conference call by telephone, please dial 1-866-744-5399 from the United States, or +972-3-918-0644 internationally. The call will also be available via live webcast through Compugen's website, located atthe
COMPUGEN - COMPUGEN TO RELEASE FIRST QUARTER 2021 RESULTS Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, announced today that the Company will release its first quarter 2021 financial results on Thursday, May 13, 2021 before the U.S. financial markets open. Management will host a conference call and webcast to review the results and provide a corporate update at 8:30 AM ET. COMPUGEN REPORTS FOURTH QUARTER AND FULL YEAR 2020 RESULTS The Company will hold a conference call today, February 25, 2021, at 8:30 AM ET to review its fourth quarter and full year 2020 results. To access the conference call by telephone, please dial 1-866-744-5399 from the United States, or +972-3-918-0610 internationally. The call will also be available via live webcast through Compugen's websiteBISPECIFIC PRODUCTS
Bispecific Products. Bispecific and multi-specific antibodies represent an emerging class of therapeutics. Unlike traditional antibodies, these are capable of binding to multiple distinct antigens simultaneously and may offer certain benefits such as improved response rates. Compugen licensed to AstraZeneca one of its pipelineprograms to
COMPUGEN - NEWS & EVENTS - EVENTS Abstract: 2504. Session: Developmental Therapeutics—Immunotherapy. Date and Time: June 7, 202, 3:00 PM – 6:00 PM EDT. The abstract will be made available by ASCO on May 19, 2021, at 5:00 PM EDT on ASCO.org. The presentation will be made available on Compugen's website at www.cgen.com following the conclusion of the presentation. Add to COMPUGEN - STOCK INFORMATION Compugen is followed by the analysts listed above. Please note that any opinions, estimates or forecasts regarding Compugen’s performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Compugen or itsmanagement.
COMPUGEN - COMPUGEN TO PRESENT AT THE OPPENHEIMER 31ST Compugen Ltd. (NASDAQ: CGEN), a leader in predictive discovery and development of first-in-class therapeutics for cancer immunotherapy, today announced that management will present at the Oppenheimer 31 st Annual Healthcare Conference (virtual), on Tuesday, March 16, 2021 at 10:40 AM ET. A live webcast of the presentation will be available onCompugen's website.
WWW.CGEN.COM
www.cgen.com
COM902/TIGIT
COM902 is a therapeutic antibody against the immuno-oncology target TIGIT, a recently validated immune checkpoint. Compugen is ultimately developing COM902 to broaden the clinical potential of its PVRIG inhibitor, COM701 allowing to comprehensively block the DNAM axis by the parallel inhibition of TIGIT and PVRIG.CGEN.COM
cgen.com
HOME - COMPUGENABOUT USDISCOVERYPIPELINECOLLABORATIONSINVESTORSCLINICAL TRIALS Our Triple Combination Approach. We believe that the PVRIG pathway we discovered is a potential paradigm shifting target to enhance patient responses to cancer immunotherapies and may provide new treatment options as monotherapy or in combination with other immune checkpoints to expand the reach of cancer immunotherapies to new patientPIPELINE - COMPUGEN
Pipeline Overview COM701/PVRIG COM902/TIGIT ILDR2/BAY 1905254 Myeloid Programs Bispecific Products Overview COM701/PVRIG COM902/TIGIT ILDR2/BAY 1905254 Myeloid Programs Bispecific Products Overview Despite significant advances in oncology, there is still a large unmet need in treating patients with solid tumors, especially those with advanced disease. Our approach begins with ourCOM701/PVRIG
COM701/PVRIG. Compugen’s lead candidate, COM701, is a first-in-class immunotherapy targeting PVRIG, a novel immune checkpoint that our team computationally discovered and validated in preclinical studies. Clinical data of COM701, as a monotherapy and in combination with PD-1 blockers, have demonstrated initial signs of antitumor activity RESEARCH ASSOCIATE /ASSOCIATE SCIENTIST (TEMP. JUNE 2021 Job Description The Research associate /Associate Scientist will report to the Associate Director in the Research andDrug Discovery group. The candidate will be responsible for designing and executing experimentalsystems for functional validation of novel immunomodulatory molecules discovered by Compugen,including target validation activities, research tools generation and QC, expressionCOMPUGEN - OVERVIEW
Compugen is a clinical-stage drug discovery and development company utilizing a broadly applicable, predictive computational discovery platform to identify novel drug targets and new biological pathways and develop therapeutics in the field of cancer immunotherapy. Recognizing the potential of immuno-oncology to shift the cancertreatment
LEADERSHIP - COMPUGEN Leadership Overview Leadership Collaborations Overview Leadership Collaborations Management Compugen’s leadership team is comprised of seasoned executives with deep knowledge and expertise in the biopharmaceutical industry. Anat Cohen-Dayag, Ph.D. President and CEO Ari Krashin Chief Financial and Operating Officer Henry Adewoye, M.D. Senior Vice President and Chief Medical Officer Oliver COMPUGEN - COMPUGEN TO RELEASE FIRST QUARTER 2021 RESULTS Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, announced today that the Company will release its first quarter 2021 financial results on Thursday, May 13, 2021 before the U.S. financial markets open. Management will host a conference call and webcast to review the results and provide a corporate update at 8:30 AM ET. COMPUGEN - COMPUGEN REPORTS FIRST QUARTER 2021 RESULTS The Company will hold a conference call today, May 13, 2021, at 8:30 AM ET to review its first quarter 2021 results. To access the conference call by telephone, please dial 1-866-744-5399 from the United States, or +972-3-918-0644 internationally. The call will also be available via live webcast through Compugen's website, located atthe
COMPUGEN ANNOUNCES DATA UPDATE FROM COM701 PHASE 1 HOLON, Israel, Feb. 25, 2021 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, reported today updated data from its Phase 1 dose escalation and expansion study of COM701 as a monotherapy, and in a dose escalation combination study with Opdivo® (nivolumab). ). COM701 is a first-in-class investigational COMPUGEN - COMPUGEN TO PRESENT UPDATED DATA ON COM701 Abstract: 2504. Session: Developmental Therapeutics—Immunotherapy. Date and Time: June 7, 202, 3:00 PM – 6:00 PM EDT. The abstract will be made available by ASCO on May 19, 2021, at 5:00 PM EDT on ASCO.org. The presentation will be made available on Compugen's website at www.cgen.com following the conclusion of the presentation. Add to HOME - COMPUGENABOUT USDISCOVERYPIPELINECOLLABORATIONSINVESTORSCLINICAL TRIALS Our Triple Combination Approach. We believe that the PVRIG pathway we discovered is a potential paradigm shifting target to enhance patient responses to cancer immunotherapies and may provide new treatment options as monotherapy or in combination with other immune checkpoints to expand the reach of cancer immunotherapies to new patientPIPELINE - COMPUGEN
Pipeline Overview COM701/PVRIG COM902/TIGIT ILDR2/BAY 1905254 Myeloid Programs Bispecific Products Overview COM701/PVRIG COM902/TIGIT ILDR2/BAY 1905254 Myeloid Programs Bispecific Products Overview Despite significant advances in oncology, there is still a large unmet need in treating patients with solid tumors, especially those with advanced disease. Our approach begins with ourCOM701/PVRIG
COM701/PVRIG. Compugen’s lead candidate, COM701, is a first-in-class immunotherapy targeting PVRIG, a novel immune checkpoint that our team computationally discovered and validated in preclinical studies. Clinical data of COM701, as a monotherapy and in combination with PD-1 blockers, have demonstrated initial signs of antitumor activity RESEARCH ASSOCIATE /ASSOCIATE SCIENTIST (TEMP. JUNE 2021 Job Description The Research associate /Associate Scientist will report to the Associate Director in the Research andDrug Discovery group. The candidate will be responsible for designing and executing experimentalsystems for functional validation of novel immunomodulatory molecules discovered by Compugen,including target validation activities, research tools generation and QC, expressionCOMPUGEN - OVERVIEW
Compugen is a clinical-stage drug discovery and development company utilizing a broadly applicable, predictive computational discovery platform to identify novel drug targets and new biological pathways and develop therapeutics in the field of cancer immunotherapy. Recognizing the potential of immuno-oncology to shift the cancertreatment
LEADERSHIP - COMPUGEN Leadership Overview Leadership Collaborations Overview Leadership Collaborations Management Compugen’s leadership team is comprised of seasoned executives with deep knowledge and expertise in the biopharmaceutical industry. Anat Cohen-Dayag, Ph.D. President and CEO Ari Krashin Chief Financial and Operating Officer Henry Adewoye, M.D. Senior Vice President and Chief Medical Officer Oliver COMPUGEN - COMPUGEN TO RELEASE FIRST QUARTER 2021 RESULTS Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, announced today that the Company will release its first quarter 2021 financial results on Thursday, May 13, 2021 before the U.S. financial markets open. Management will host a conference call and webcast to review the results and provide a corporate update at 8:30 AM ET. COMPUGEN - COMPUGEN REPORTS FIRST QUARTER 2021 RESULTS The Company will hold a conference call today, May 13, 2021, at 8:30 AM ET to review its first quarter 2021 results. To access the conference call by telephone, please dial 1-866-744-5399 from the United States, or +972-3-918-0644 internationally. The call will also be available via live webcast through Compugen's website, located atthe
COMPUGEN ANNOUNCES DATA UPDATE FROM COM701 PHASE 1 HOLON, Israel, Feb. 25, 2021 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, reported today updated data from its Phase 1 dose escalation and expansion study of COM701 as a monotherapy, and in a dose escalation combination study with Opdivo® (nivolumab). ). COM701 is a first-in-class investigational COMPUGEN - COMPUGEN TO PRESENT UPDATED DATA ON COM701 Abstract: 2504. Session: Developmental Therapeutics—Immunotherapy. Date and Time: June 7, 202, 3:00 PM – 6:00 PM EDT. The abstract will be made available by ASCO on May 19, 2021, at 5:00 PM EDT on ASCO.org. The presentation will be made available on Compugen's website at www.cgen.com following the conclusion of the presentation. Add to COMPUGEN - COMPUGEN TO RELEASE FIRST QUARTER 2021 RESULTS Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, announced today that the Company will release its first quarter 2021 financial results on Thursday, May 13, 2021 before the U.S. financial markets open. Management will host a conference call and webcast to review the results and provide a corporate update at 8:30 AM ET. COMPUGEN - COMPUGEN REPORTS FIRST QUARTER 2021 RESULTS The Company will hold a conference call today, May 13, 2021, at 8:30 AM ET to review its first quarter 2021 results. To access the conference call by telephone, please dial 1-866-744-5399 from the United States, or +972-3-918-0644 internationally. The call will also be available via live webcast through Compugen's website, located atthe
CLINICAL TRIALS
Clinical Trials COM701/PVRIG COM902/TIGIT COM701 Triple Combination BAY 1905254 COM701/PVRIG COM902/TIGIT COM701 Triple Combination BAY 1905254 Phase 1 Study of COM701 in Patients with Advanced Solid Tumors This study is designed to evaluate the safety, tolerability and preliminary antitumor activity of COM701, an anti-PVRIG antibody, as monotherapy and in combination with LEADERSHIP - COMPUGEN Leadership Overview Leadership Collaborations Overview Leadership Collaborations Management Compugen’s leadership team is comprised of seasoned executives with deep knowledge and expertise in the biopharmaceutical industry. Anat Cohen-Dayag, Ph.D. President and CEO Ari Krashin Chief Financial and Operating Officer Henry Adewoye, M.D. Senior Vice President and Chief Medical Officer OliverWWW.CGEN.COM
www.cgen.com
COMPUGEN - COMPUGEN FIRST QUARTER 2021 CONFERENCE CALL To opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. After submitting your request, you will receive an activation email to the requested email address. COMPUGEN - COMPUGEN EXPANDS CLINICAL COLLABORATION Cohort expansion study expected to commence in the second quarter of 2021 Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, announced today the expansion of its clinical collaboration agreement with Bristol Myers Squibb. Under the amended agreement, Bristol Myers Squibb will supply Opdivo® (nivolumab), its PD-1 COMPUGEN - COMPUGEN TO PARTICIPATE AT SITC'S TARGETS FOR Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today announced that Eran Ophir, Ph.D., Vice President Research and Drug Discovery at Compugen, will participate at the Society for Immunotherapy of Cancer (SITC) Targets for Cancer Immunotherapy: A Deep Dive Seminar Series .ILDR2/BAY 1905254
ILDR2/BAY 1905254. Myeloid Programs. Bispecific Products. ILDR2 is a novel immune checkpoint target with a unique mechanism of action discovered computationally by Compugen. While ILDR2 demonstrates an inhibitory effect on T cells, consistent with its role as an immune checkpoint ligand, preclinical data suggest that ILDR2 inhibitionexerts its
CGEN.COM
cgen.com
Accesibility
*
Fonts size
*
Underline links
*
Bigger tabs outline
*
Dark contrast
*
Bright contrast
*
Black & white
*
Simple font
*
Dyslexic font
*
Stop animations
* Publications
* Media Center
* Press Releases
* Events
* Media Coverage
* Careers
* Overview
* Careers in Israel
* Careers in the US
* Contact Us
* ABOUT US
* Overview
* Management
* Board of Directors * Scientific Advisory Board * Strategic Advisors* Locations
* DISCOVERY
* Overview
* Predictive Discovery* Target Discovery
* Target Validation
* Publications
* PIPELINE
* Overview
* Immuno-Oncology
* Autoimmune Diseases* Clinical Trials
* Publications
* COLLABORATIONS
* Overview
* Bayer
* Bristol-Myers Squibb* AstraZeneca
* Johns Hopkins University* INVESTORS
* Overview
* Press Releases
* Events
* Corporate Presentation * Annual and Quarterly Reports* Proxy Statement
* SEC Filings
* Stock Quote
* Analyst Coverage
* Corporate Governance * Request Information*
From Code
to Cure®
pioneer in computational drug target discovery Innovative immuno-oncology pipeline*
*
*
NEWS
May 06, 2020
COMPUGEN REPORTS FIRST QUARTER 2020 RESULTSApr 27, 2020
COMPUGEN PRESENTS DATA UPDATE FROM ONGOING PHASE 1 TRIAL OF COM701 AT THE 2020 AACR VIRTUAL ANNUAL MEETINGALL NEWS
RESEARCH AND DEVELOPMENT Our optimized process for predictive discovery of novel drug targetsREAD MORE
CLINICAL DEVELOPMENT Our ongoing Phase 1 study of COM701, a first-in-class antibody targeting PVRIG, a novel ICP target READ MORE COMPUGEN, FROM CODE TO CURE®(VIDEO)OUR PIPELINE
COM701/PVRIG
COM701 is a first-in-class therapeutic antibody targeting PVRIG, a novel immune checkpoint target candidate discovered computationally byCompugen. READ MORE
BAY 1905254/ILDR2 (PARTNERED) ILDR2 (formerly CGEN-15001T) is a novel immune checkpoint target discovered by Compugen and partnered to Bayer. READ MORECOM902/TIGIT
COM902, an anti-TIGIT inhibitor, is being developed as an integral component of the COM701 program, to facilitate the combination strategy for COM701. COM902 is being developed as an integral component of the COM701 program, to provide the company with an internally-developed antibody to facilitate the combination strategy for COM701 READ MORE MULTIPLE MYELOID PROGRAMS Compugen’s early stage programs are focused largely on myeloid targets addressing a range of mechanisms of action. READ MOREMay 06, 2020
COMPUGEN FIRST QUARTER 2020 CONFERENCE CALLHolon, Israel
Apr 27, 2020
COM701 DEMONSTRATES PRELIMINARY ANTITUMOR ACTIVITY AS MONOTHERAPY AND IN COMBINATION WITH NIVOLUMAB IN PATIENTS WITH ADVANCED SOLID TUMORS(ORAL PRESENTATION)
2020 AACR Virtual Annual Meeting IFeb 20, 2020
COMPUGEN FOURTH QUARTER AND FULL YEAR 2019 CONFERENCE CALL Holon, Israel MORE EVENTSCOLLABORATIONS
Click here for more info about partnering with Compugen* ABOUT US
* Overview
* Management
* Board of Directors * Scientific Advisory Board * Strategic Advisors* Locations
* DISCOVERY
* Overview
* Predictive Discovery* Target Discovery
* Target Validation
* Publications
* PIPELINE
* Overview
* Immuno-Oncology
* Autoimmune Diseases* Clinical Trials
* Publications
* COLLABORATIONS
* Overview
* Bayer
* Bristol-Myers Squibb* AstraZeneca
* Johns Hopkins University* INVESTORS
* Overview
* Press Releases
* Events
* Corporate Presentation * Annual and Quarterly Reports* Proxy Statement
* SEC Filings
* Stock Quote
* Analyst Coverage
* Corporate Governance * Request Information* Media Center
* Careers
* Contact Us
* Terms & Privacy
Created by: Design-factory All rights reserved to Compugen Ltd. 2015Details
Copyright © 2024 ArchiveBay.com. All rights reserved. Terms of Use | Privacy Policy | DMCA | 2021 | Feedback | Advertising | RSS 2.0